MedTrace Logo

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

NCT03805841 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2023-06-28

Study results available
· View outcomes & findings →

Summary

Open-label, Phase 2, single treatment arm, 3 cohorts

Conditions

  • NSCLC, Stage IV
  • NSCLC Stage IIIB
  • NSCLC, Stage IIIC
  • NSCLC, Recurrent
  • EGFR Exon 20 Insertion Mutation
  • HER2-activating Mutation
  • ERBB Fusion
  • NRG1 Fusion

Interventions

DRUG

tarloxotinib bromide

weekly intravenous infusion

Sponsors & Collaborators

  • Rain Oncology Inc

    lead INDUSTRY

Principal Investigators

  • Stephen V Liu, MD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-13
Primary Completion
2021-04-09
Completion
2021-04-23
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03805841 on ClinicalTrials.gov